| Log in

Wockhardt says FDA alert affects potential sales of $100M

23 May, 2013

Drug maker Wockhardt Ltd said up to $100 million in annualised revenue could be lost as a result of a U.S. Food and Drug Administration “import alert” on one of its plants, but said it should be able to restore most of that within 6 to 9 months by shifting production elsewhere.

“That is a worst-case scenario,” Wockhardt Chairman Habil Khorakiwala said, referring to the $100 million, in a conference call with reporters.

Wockhardt shares fell 20 percent on Thursday to their lowest level in more than seven months after the U.S. drug regulator published an “import alert” on one of its manufacturing facilities.

The U.S. Food and Drug Administration published the alert, dated May 22, on a Wockhardt facility in Aurangabad in the western Indian state of Maharashtra, according to the regulator’s website.


Leave Your Comment
Wockhardt gets warning from USFDA over Chikalthana plant at Aurangabad

Wockhardt gets warning from USFDA over Chikalthana plant at Aurangabad

Lohit Jagwani 4 years ago
In another setback to Mumbai-based generic drugmaker Wockhardt Ltd, it has...
Wockhardt raises $13.4M through IPO of European arm

Wockhardt raises $13.4M through IPO of European arm

Bhawna Gupta 4 years ago
Mumbai-based generic drugmaker Wockhardt Ltd has raised CHF 11.86 million ($13...
USFDA bans import of drugs from Wockhardt’s Ankleshwar plant

USFDA bans import of drugs from Wockhardt’s Ankleshwar plant

PTI 1 year ago
In yet another blow to drug maker Wockhardt, US Food and Drug Administration ...
No Comments

Wockhardt says FDA alert affects potential sales of $100M

Powered by WordPress.com VIP